What Is an Androgen Receptor Inhibitor?

An androgen receptor inhibitor is a drug that blocks the androgen receptor, a protein that normally receives signals from male hormones like testosterone and dihydrotestosterone and translates them into cellular activity. By occupying or disabling this receptor, these drugs shut down hormonal signaling that fuels the growth of prostate cancer, certain types of acne, and other androgen-driven conditions. The category has expanded considerably since the first drugs of this kind appeared decades ago, and understanding the differences between older and newer versions matters for anyone trying to make sense of a treatment plan.

How Androgen Receptor Signaling Works

To understand what these drugs block, it helps to know what the androgen receptor does when left alone. Androgens like testosterone circulate in the blood and enter cells, where they bind to the androgen receptor sitting in the cell’s cytoplasm. Once a hormone latches on, the receptor changes shape and moves into the cell nucleus, where it switches on genes that drive cell growth, division, and survival.¹ In normal prostate tissue, this is part of routine maintenance. But in prostate cancer, the same signaling pathway gets hijacked: the cancer cells rely on it to keep growing and to resist the body’s natural signals to self-destruct.²

That reliance on androgen signaling is exactly what makes the receptor such an attractive drug target. The idea dates back to 1941, when Charles Huggins and Clarence Hodges showed that prostate tumors shrank when androgen levels dropped, a finding that eventually earned a Nobel Prize.³ For decades, the primary strategy was simply to cut off the hormone supply through surgical or chemical castration. Androgen receptor inhibitors represent a more targeted evolution of that idea: instead of reducing hormone levels alone, they go directly to the receptor and block it from functioning.

Steroidal Versus Nonsteroidal Drugs

Before getting into generations, there is a basic chemical split in how these drugs are built. Some androgen receptor inhibitors are steroidal, meaning their molecular structure resembles natural steroid hormones. These drugs, like cyproterone acetate, do two things at once: they compete with testosterone for a spot on the receptor, and they also mimic the body’s feedback signals to the brain, telling the hypothalamus that hormone levels are high enough, which causes testosterone production to drop.⁴ Nonsteroidal versions, like flutamide, take a different approach. They block the receptor in target tissues but do not trigger that feedback loop in the brain. The result is that testosterone levels in the blood actually rise, even though the receptor is blocked.⁵ This is why nonsteroidal drugs are typically given alongside hormone-lowering therapy rather than on their own.

First-Generation and Second-Generation Drugs

The distinction that matters most in current clinical practice is between first-generation and second-generation androgen receptor inhibitors. First-generation drugs, including flutamide, bicalutamide, and nilutamide, established the basic principle that blocking the receptor directly could help treat prostate cancer. But they have a well-known weakness: they do not completely shut down the receptor. In cancer cells that produce high levels of the androgen receptor, these drugs can paradoxically start acting like weak activators, doing some of the same work that the hormones themselves would do.²

Second-generation drugs were developed specifically to overcome that limitation. Enzalutamide, apalutamide, darolutamide, and abiraterone acetate are the four FDA-approved agents in this class.⁶ They bind the androgen receptor more tightly, do not flip into agonist mode, and block more of the downstream steps that first-generation drugs miss. Abiraterone works a bit differently from the others. Rather than sitting on the receptor itself, it blocks an enzyme called CYP17A1 that the body uses to manufacture androgens, starving the receptor of its hormone supply. But because the net result is still the suppression of androgen receptor signaling, it gets grouped with the second-generation agents in practice.

One practical difference among the newer drugs involves the brain. Darolutamide was specifically designed to have low penetration of the blood-brain barrier. In animal studies, its brain-to-blood ratio was roughly ten times lower than that of enzalutamide.⁷ This matters because central nervous system side effects like fatigue, falls, and seizures have been a concern with enzalutamide. Whether darolutamide’s lower brain penetration translates into meaningfully fewer cognitive side effects for all patients is still being sorted out, but it is one reason oncologists sometimes prefer it for older or frailer patients.

Where These Drugs Are Used

Prostate cancer is by far the biggest arena for androgen receptor inhibitors, but it is not the only one.

Prostate Cancer

The role of these drugs has expanded dramatically over the past decade. They were initially approved for men whose cancer had stopped responding to standard hormone therapy, a stage called castration-resistant prostate cancer. Enzalutamide and abiraterone both showed survival improvements in that setting.⁸ Since then, approvals have moved earlier and earlier in the disease course. These drugs are now used alongside standard hormone therapy for men who are newly diagnosed with metastatic prostate cancer that still responds to hormones, a condition called metastatic castration-sensitive prostate cancer. Adding an androgen receptor pathway inhibitor to standard hormone therapy in that setting reduced the risk of death by roughly 40% and cut the risk of progression to castration-resistant disease by more than half.⁹ Apalutamide and darolutamide have also been approved for non-metastatic castration-resistant prostate cancer, meaning cancer that has not spread but is rising despite low testosterone.¹⁰

Acne

In 2020, the FDA approved clascoterone, a topical androgen receptor inhibitor, for acne. Applied as a cream, it works locally in the skin to block the androgen receptor in sebaceous glands, which are the oil-producing glands that contribute to breakouts. Clascoterone was the first genuinely new class of acne treatment in nearly four decades.¹¹ Because it acts topically, it avoids the systemic hormonal effects that make oral anti-androgens problematic, especially for male patients.¹²

Breast Cancer

A subset of triple-negative breast cancers express the androgen receptor, and researchers are investigating whether blocking that receptor could help treat them. Bicalutamide and enzalutamide are both being tested in clinical protocols for androgen receptor-positive triple-negative breast cancer.¹³ Early lab work also suggests that combining an androgen receptor blocker with a PI3K inhibitor may be especially effective for tumors that carry certain mutations.¹⁴ This is still investigational and not standard care, but it represents one of the more promising expansions of the drug class beyond prostate cancer.

Side Effects and Metabolic Risks

Because androgens affect nearly every organ system, blocking them has consequences beyond the tumor. Side effects depend on which drug is used, whether it is combined with standard hormone-lowering therapy, and the patient’s age and baseline health.

Cardiovascular risk is a significant concern. A meta-analysis of 26 randomized trials found that androgen receptor pathway inhibitors increased the risk of serious cardiac events, including heart failure and atrial fibrillation, and roughly doubled the risk of severe hypertension compared with control groups.¹⁵ The risks are not identical across drugs. Abiraterone showed a stronger association with cardiac disorders and hypertension, while enzalutamide was more closely linked to atrial fibrillation.¹⁵ A separate review noted that these drugs add cardiovascular risk on top of what standard hormone therapy already does, since androgen deprivation on its own reduces muscle mass and increases body fat, raising the baseline risk for diabetes and high blood pressure.¹⁶

Metabolic changes come on fast. Within the first year of combined androgen deprivation and androgen receptor pathway inhibitor therapy, the cumulative rate of metabolic syndrome reached nearly 40%, with men in their seventies affected most heavily. Hypertension was the most common component.¹⁷ This suggests that monitoring should not wait until heart problems appear. Early screening for blood pressure, blood sugar, and cholesterol changes is something oncologists are increasingly incorporating.

Bone health is another area of concern. A pooled analysis of randomized trials found that androgen receptor signaling inhibitors more than doubled the risk of fractures and falls compared with controls.¹⁸ Bone density loss from androgen deprivation therapy is already a known issue; adding a receptor inhibitor compounds it. Bone-protective agents and regular bone density monitoring are standard recommendations for patients on these regimens.

Why These Drugs Eventually Stop Working

One of the most frustrating realities of androgen receptor inhibitor therapy is that prostate cancers nearly always find a way around them. The cancer evolves under the pressure of treatment, and several distinct escape routes have been identified.

The most studied involves something called AR-V7, a shortened version of the androgen receptor that cancer cells produce by reading the receptor’s genetic instructions differently. AR-V7 lacks the part of the receptor where drugs like enzalutamide and abiraterone bind, so it stays permanently active regardless of whether those drugs are present. In one study, none of the enzalutamide-treated patients who tested positive for AR-V7 in their blood responded to the drug, compared with a 53% response rate in patients who were AR-V7 negative. The pattern was similar for abiraterone, where AR-V7 positive patients had a 0% response rate versus 68% in negative patients.¹⁹ Survival differences were stark as well, with AR-V7 positive patients on enzalutamide surviving a median of roughly five and a half months compared with much longer in AR-V7 negative patients.

Other resistance mechanisms include the cancer making extra copies of the androgen receptor gene so that even partially blocked signaling is enough to drive growth, point mutations in the receptor that change its shape so the drug no longer fits, and bypass signaling through other receptors like the glucocorticoid receptor that can substitute for some androgen receptor functions.²⁰

Perhaps the most troubling escape route is neuroendocrine transformation, where prostate cancer cells under treatment pressure essentially change their identity. They stop looking and behaving like prostate cells and start resembling neuroendocrine cells, which do not rely on androgen signaling at all. Research has identified specific molecular pathways that drive this transformation, involving proteins that rewrite which genes are active in the cell.²¹ Neuroendocrine prostate cancer is aggressive and current treatments for it remain limited.²²

Drugs That Destroy the Receptor Instead of Blocking It

Because blocking the receptor still leaves it physically intact and capable of being reactivated, researchers have been developing drugs that destroy the androgen receptor entirely. The most prominent approach uses molecules called PROTACs, which work like molecular matchmakers. A PROTAC molecule has two ends: one grabs the androgen receptor and the other grabs a cellular recycling machine called an E3 ubiquitin ligase. By bringing them together, the PROTAC tags the receptor for destruction by the cell’s own protein-disposal system.²³

Bavdegalutamide (ARV-110) is the furthest along in development. In lab studies, it degrades both normal androgen receptors and most of the clinically relevant mutant versions at very low concentrations.²³ Several PROTAC-based androgen receptor degraders have advanced into early-phase clinical trials.²⁴ The hope is that destroying the receptor rather than just blocking it might overcome many of the resistance mechanisms that limit current drugs, including receptor overproduction and mutations in the drug-binding region.

Targeting a Different Part of the Receptor

Every approved androgen receptor inhibitor targets the same region of the protein: the ligand-binding domain, which is the pocket where hormones normally dock. That is also the region that AR-V7 and similar truncated receptor variants lack entirely, which is why those variants can evade current drugs. A fundamentally different strategy is to go after a separate part of the receptor called the N-terminal domain, which is required for all forms of the receptor to switch on genes, including the truncated splice variants.²⁵

Experimental compounds targeting this region have shown the ability to block both the full-length receptor and variant forms like AR-V7, something that neither enzalutamide nor bicalutamide can do.²⁶ The N-terminal domain is structurally flexible and disordered, which historically made it a difficult drug target. But high-throughput screening has identified small molecules that bind to it and suppress the receptor’s activity, and some of these compounds have moved into clinical testing.²⁷ If these drugs prove effective and tolerable in people, they would represent the first approach capable of shutting down androgen receptor signaling regardless of which variant of the receptor the cancer is using. For patients whose cancers have evolved past current therapies, that could be a meaningful shift.

1
Tissue and Cell. Detection of the nuclear translocation of androgen receptor using quantitative and automatic cell imaging analysis
2
PubMed Central. Practical implications of androgen receptor inhibitors for prostate cancer treatment
3
PubMed Central. Eighty Years of Targeting Androgen Receptor Activity in Prostate Cancer: The Fight Goes on
4
Cancer. Antiandrogenic drugs
5
PubMed. Steroidal and nonsteroidal antiandrogens: chemical structures, mechanisms of action and clinical applications
6
Frontiers in Oncology. Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer
7
Journal of Clinical Oncology. Blood-brain barrier penetration of [14C]darolutamide compared with [14C]enzalutamide in rats using whole body autoradiography
8
PubMed Central. Androgen receptor antagonists in castration-resistant prostate cancer
9
PubMed Central. Survival benefit associated with first-line androgen receptor pathway inhibitors for de novo metastatic castration-sensitive prostate cancer
10
Cell Death & Disease. Second generation androgen receptor antagonists and challenges in prostate cancer treatment
11
PubMed. Clascoterone cream (1%) topical androgen receptor inhibitor for the treatment of acne in patients 12 years and older
12
PubMed. Clascoterone: A Novel Topical Androgen Receptor Inhibitor for the Treatment of Acne
13
PubMed Central. Anti-Androgenic Therapies Targeting the Luminal Androgen Receptor of a Typical Triple-Negative Breast Cancer
14
PubMed Central. PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors
15
PubMed Central. Cardiovascular events among men with prostate cancer treated with androgen receptor signaling inhibitors: a systematic review, meta-analysis, and network meta-analysis
16
PubMed Central. Cardiovascular Risk in Prostate Cancer: JACC: CardioOncology State-of-the-Art Review
17
JAMA Oncology. Metabolic Dysfunction After Initiation of Androgen Receptor Pathway Inhibitors in Prostate Cancer
18
PubMed. Risk of Fractures and Falls in Men with Advanced or Metastatic Prostate Cancer Receiving Androgen Deprivation Therapy and Treated with Novel Androgen Receptor Signalling Inhibitors: A Systematic Review and Meta-analysis of Randomised Controlled Trials
19
PubMed Central. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer
20
Nature Reviews Urology. Resistance to second-generation androgen receptor antagonists in prostate cancer
21
Cell Death Discovery. Androgen deprivation induces neuroendocrine phenotypes in prostate cancer cells through CREB1/EZH2-mediated downregulation of REST
22
PubMed Central. Mechanisms of neuroendocrine differentiation in castration-resistant prostate cancer and advances in the treatment of neuroendocrine prostate cancer
23
PubMed Central. Preclinical Evaluation of Bavdegalutamide (ARV-110), a Novel PROteolysis TArgeting Chimera Androgen Receptor Degrader
24
PubMed. Targeting androgen receptor degradation with PROTACs from bench to bedside
25
PubMed. Targeting the N-terminal domain of the androgen receptor: The effective approach in therapy of CRPC
26
Journal of Clinical Investigation. An androgen receptor N-terminal domain antagonist for treating prostate cancer
27
PubMed Central. N-terminal domain of androgen receptor is a major therapeutic barrier and potential pharmacological target for treating castration resistant prostate cancer: a comprehensive review